BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 15128793)

  • 1. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function.
    Doody AD; Kovalchin JT; Mihalyo MA; Hagymasi AT; Drake CG; Adler AJ
    J Immunol; 2004 May; 172(10):6087-92. PubMed ID: 15128793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8+ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages.
    Tobian AA; Canaday DH; Boom WH; Harding CV
    J Immunol; 2004 May; 172(9):5277-86. PubMed ID: 15100266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes.
    Oizumi S; Strbo N; Pahwa S; Deyev V; Podack ER
    J Immunol; 2007 Aug; 179(4):2310-7. PubMed ID: 17675492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
    Machy P; Serre K; Baillet M; Leserman L
    J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential kinetics of antigen dependency of CD4+ and CD8+ T cells.
    Rabenstein H; Behrendt AC; Ellwart JW; Naumann R; Horsch M; Beckers J; Obst R
    J Immunol; 2014 Apr; 192(8):3507-17. PubMed ID: 24639353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming.
    Schlecht G; Loucka J; Najar H; Sebo P; Leclerc C
    J Immunol; 2004 Nov; 173(10):6089-97. PubMed ID: 15528345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II.
    SenGupta D; Norris PJ; Suscovich TJ; Hassan-Zahraee M; Moffett HF; Trocha A; Draenert R; Goulder PJ; Binder RJ; Levey DL; Walker BD; Srivastava PK; Brander C
    J Immunol; 2004 Aug; 173(3):1987-93. PubMed ID: 15265933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.
    Zhou G; Ding ZC; Fu J; Levitsky HI
    J Immunol; 2011 Feb; 186(4):2148-55. PubMed ID: 21242518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells.
    Pooley JL; Heath WR; Shortman K
    J Immunol; 2001 May; 166(9):5327-30. PubMed ID: 11313367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function.
    Dumortier H; van Mierlo GJ; Egan D; van Ewijk W; Toes RE; Offringa R; Melief CJ
    J Immunol; 2005 Jul; 175(2):855-63. PubMed ID: 16002683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat shock fusion protein gp96-Ig mediates strong CD8 CTL expansion in vivo.
    Strbo N; Yamazaki K; Lee K; Rukavina D; Podack ER
    Am J Reprod Immunol; 2002 Oct; 48(4):220-5. PubMed ID: 12516632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose-regulated protein 94/glycoprotein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo.
    Baker-LePain JC; Sarzotti M; Nicchitta CV
    J Immunol; 2004 Apr; 172(7):4195-203. PubMed ID: 15034032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased numbers and suppressive activity of regulatory CD25(+)CD4(+) T lymphocytes in the absence of CD4 engagement by MHC class II molecules.
    Shen X; Niu C; König R
    Cell Immunol; 2013 Apr; 282(2):117-28. PubMed ID: 23770721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.
    Adams EW; Ratner DM; Seeberger PH; Hacohen N
    Chembiochem; 2008 Jan; 9(2):294-303. PubMed ID: 18186095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H2-M3-restricted T cells participate in the priming of antigen-specific CD4+ T cells.
    Chow MT; Dhanji S; Cross J; Johnson P; Teh HS
    J Immunol; 2006 Oct; 177(8):5098-104. PubMed ID: 17015693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep.
    Rojas JM; Rodríguez-Calvo T; Peña L; Sevilla N
    Vaccine; 2011 Sep; 29(40):6848-57. PubMed ID: 21807057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide.
    Grohmann U; Fioretti MC; Bianchi R; Belladonna ML; Ayroldi E; Surace D; Silla S; Puccetti P
    Crit Rev Immunol; 1998; 18(1-2):87-98. PubMed ID: 9419451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.